Author Archives: admin


Regenerative Medicine (Bone and Joint) Market to Score Past US$ 14990.0 Million Valuation by 2027: CMI KSU | The Sentinel Newspaper – KSU | The…

Regenerative medicines are medical products or active pharmaceutical ingredients that have the ability to cure or replace organs and tissues organs damaged by various factors such as aging, diseases, trauma, and can also be used to provide stability in congenital disorders. Regenerative medicine for bone and joint is considered an emerging and promising field.

Statistics:

The globalregenerative medicine (bone and joint) marketis estimated to account forUS$ 7,189.8 Mnin terms of value in2020and is expected to reachUS$ 14,990.0 Mnby the end of2027.

GlobalRegenerative Medicine (Bone and Joint)Market: Drivers

Approval and launch of new products is expected to propel growth of the global regenerative medicine (bone and joint) market over the forecast period. For instance, in January 2020, Carmell Therapeutics received clearance from the U.S. Food and Drug Administration (U.S. FDA) for Investigational New Drug Application for the companys first product, which is a bone healing accelerant (BHA).

Request for a Sample Report of Orthopedic Regenerative Medicine Market:https://www.coherentmarketinsights.com/insight/request-sample/3566

GlobalRegenerative Medicine (Bone and Joint)Market: Opportunities

R&D of new products is expected to offer lucrative growth opportunities for players in the global regenerative medicine (bone and joint) market. For instance, in June 2019, Personalized Stem Cells, Inc. submitted an Investigational New Drug Application (IND) to the U.S. FDA for utilizing patients own adipose-derived stem cells to treat their osteoarthritis.

GlobalRegenerative Medicine (Bone and Joint)Market: Restraints

Ethical issues and post implantation infections are hindering growth of the global regenerative medicine (bone and joint) market. Utilization of adult stem cell for research and derivation of stem cell from excess in-vitro fertilization embryo does not pose any ethical concern. However, creation of embryo for research is an ethical concern and is prohibited. Moreover, utilization of adult stem cell for commercial purposes has become a threat to mankind and is considered as an ethical issue worldwide.

Key Takeaways:

The global regenerative medicine (bone and joint) market was valued atUS$ 6,473.4 Mnin2019and is forecast to reach a value ofUS$ 14,990.0 Mnby2027at aCAGR of 11.1%between2020 and 2027. Major factor driving the growth of global regenerative medicine (bone and joint) market during the forecast period include technological advancement, and increasing prevalence of musculoskeletal disorders.

Biomaterial held dominant position in the global regenerative medicine (bone and joint) market in 2019, accounting for62.7%share in terms of value, followed by Stem Cell and Tissue Engineering, respectively. Increasing use of regenerative medicine is expected to support growth of the segment over the forecast period.

Market Trends

High prevalence of rheumatoid arthritis is expected to propel growth of the global regenerative medicine (bone and joint) market over the forecast period. For instance, according to results of a systematic analysis published in the Annals of the Rheumatic Diseases in October 2019, the global prevalence of rheumatoid arthritis was 19,965,115 in 2017, with an age-standardized prevalence rate of 246.6 cases/100,000 population, which increased by 7.4% between 1990 and 2017.

Major players in the global regenerative medicine (bone and joint) market are focused on approval and launch of new products to expand their product portfolio. For instance, in January 2020, Royal Biologics launched Magnus viable cellular bone matrix, which is an osteoconductive bone scaffold and is composed of demineralized cortical, mineralized cortical, and cancellous bone that is stored in a DMSO-free cryoprotectant.

GlobalRegenerative Medicine (Bone and Joint)Market: Competitive Landscape

Major players operating in the global regenerative medicine (bone and joint) market include, Anika Therapeutics, Inc., Arthrex, Inc., Baxter International, Inc., CONMED Corporation, DePuy Synthes, Inc., Medtronic, Plc, Smith & Nephew plc, Stryker Corporation, Zimmer Holdings, Inc., Aziyo Biologics, and Ortho Regenerative Technologies Inc.

GlobalRegenerative Medicine (Bone and Joint)Market: Key Developments

Major players in the global regenerative medicine (bone and joint) market are focused on adopting various strategies to enhance their market share. For instance, in August 2020, Ortho Regenerative Technologies Inc. announced the closing of a non-brokered US$ 2.5 million private placement of units.

Apply Promo Code STAYHOME and Get Up to 30% Discount

If you purchase the report this year:

Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/3566

Segmentation

To know the latest trends and insights prevalent in the Global Regenerative Medicine (Bone and Joint) Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/orthopedic-regenerative-medicine-market-3566

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact Us

Mr. Shah 1001 4th Ave, #3200 Seattle, WA 98154 Phone: US +12067016702 / UK +4402081334027 sales@coherentmarketinsights.com

More:
Regenerative Medicine (Bone and Joint) Market to Score Past US$ 14990.0 Million Valuation by 2027: CMI KSU | The Sentinel Newspaper - KSU | The...

Orthopedic Regenerative Medicine Market Size to Witness A Lucrative Growth Over 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika…

The Report Titled on Orthopedic Regenerative Medicine Market which provides COVID19 Impact analysis on Market Size (Production, Capacity, Value, Values & Consumption), Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis, Impact of Domestic and Market Players. Orthopedic Regenerative Medicine Market detailed study of historical and present/future market data. Economic growth, GDP (Gross Domestic Product), and inflation are some of the elements included in this report to offer crystal clear picture of the Orthopedic Regenerative Medicine industry at global level.

Orthopedic Regenerative Medicine Market competitive landscapes provides details by topmost manufactures like (Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.), including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments.

Request for a Sample Report of Orthopedic Regenerative Medicine Market:https://www.coherentmarketinsights.com/insight/request-sample/3566

Market Segmentation & Coverage:

This research report categorizes the Orthopedic Regenerative Medicine to forecast the revenues and analyze the trends in each of the following sub-markets:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Based on Geography, the Orthopedic Regenerative Medicine Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

The Orthopedic Regenerative Medicine Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Apply Promo Code STAYHOME and Get Up to 30% Discount

If you purchase the report this year:

Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/3566

The report provides insights on the following pointers:

Market Penetration: Provides comprehensive information on the market offered by the key players

Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

What is the market size and forecast of the Global Orthopedic Regenerative Medicine Market?

What are the inhibiting factors and impact of COVID-19 shaping the Global Orthopedic Regenerative Medicine Market during the forecast period?

Which are the products/segments/applications/areas to invest in over the forecast period in the Global Orthopedic Regenerative Medicine Market?

What is the competitive strategic window for opportunities in the Global Orthopedic Regenerative Medicine Market?

What are the technology trends and regulatory frameworks in the Global Orthopedic Regenerative Medicine Market?

What are the modes and strategic moves considered suitable for entering the Global Orthopedic Regenerative Medicine Market?

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact Us

Mr. Shah 1001 4th Ave, #3200 Seattle, WA 98154 Phone: US +12067016702 / UK +4402081334027 sales@coherentmarketinsights.com

Follow this link:
Orthopedic Regenerative Medicine Market Size to Witness A Lucrative Growth Over 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika...

Adult Stem Cells Market Demand, Growth Challenges, Industry Analysis And Forecasts To 2026 | Epistem Ltd.,Globalstem,Mesoblast Ltd.,Brainstorm Cell…

Overview

The report on the global Adult Stem Cells market is derived out of intense research carried out by the industry professionals. The report provides brief information on the products or services in the market and also provides information on their applications. The data experts provide information on the current scenario of the market, trends emerging in the market, etc. The Adult Stem Cells market has been segmented into various categories by the report, based on different features and attributes, in order to simplify the understanding of the vast market. The analysis would help the companies to know about various kinds of products or services in the market. The base year for the market research is 2020, the forecast would extend until the year of 2027.

Key Players: Epistem Ltd.,Globalstem,Mesoblast Ltd.,Brainstorm Cell Therapeutics Inc.,Juventas Therapeutics Inc.,Neuralstem,Beike Biotechnology Co. Ltd.,Cellerix Sa,Hybrid Organ Gmbh,Gamida Cell Ltd.,Cellular Dynamics International,International Stem Cell Corp.,Clontech,Capricor Inc.,Caladrius Biosciences Inc.,Neurogeneration,Cytori Therapeutics Inc.,Cellerant Therapeutics Inc.,Biotime Inc.,Intellicell Biosciences Inc.,Celyad

Request Sample Copy of this Report @: https://www.reportsandmarkets.com/sample-request/global-adult-stem-cells-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=jumbonews&utm_medium=41

Drivers and Risks

The report identifies the aspects that are driving off the market on the path of fast-paced growth and expansion, while also covering the factors slowing down the process of growth. The report also analyzes the levels of impact the government initiatives and policies have on the stability of the market. The report discusses the pricing margin in the market, paired with the risks bared by the market vendors. The report covers the volume trends, potential opportunities and risks, market size, etc which would help the companies entering the market to get an acute grasp of the market.

Regional Description

The report covers the Adult Stem Cells market not only at the global level but also at the regional levels. The report identifies the strengths, dominating trends, etc in the regional markets, which could be helpful in the long run. The report also provides information on the key players present in the regional markets. The report analyzes some of the important factors like imports and exports market share, market revenue, etc in the regions of North America, Europe, Latin America, Asia-Pacific, and the Middle East and Africa. The report also identifies major market areas present in these regions.

Regional Analysis For Adult Stem Cells Market

North America (the United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

The objectives of the report are:

To analyze and forecast the market size of Adult Stem Cells Industry in the global market.

To study the global key players, SWOT analysis, value and global market share for leading players.

To determine, explain and forecast the market different attributes of the products or services. This information would help the companies to understand the prominent trends that are emerging in the market and would also provide a wider by type, end use, and region.

To analyze the market potential and advantage, opportunity and challenge, restraints and risks of global key regions.

To find out significant trends and factors driving or restraining the market growth.

To analyze the opportunities in the market for stakeholders by identifying the high growth segments.

To critically analyze each submarket in terms of individual growth trend and their contribution to the market.

To understand competitive developments such as agreements, expansions, new product launches, and possessions in the market.

To strategically outline the key players and comprehensively analyze their growth strategies.

View Full Report @ https://www.reportsandmarkets.com/sample-request/global-adult-stem-cells-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=jumbonews&utm_medium=41

Key questions answered in the report:

What is the growth potential of the Adult Stem Cells market?

Which product segment will grab a lions share?

Which regional market will emerge as a frontrunner in the coming years?

Which application segment will grow at a robust rate?

What are the growth opportunities that may emerge in the Adult Stem Cells industry in the years to come?

What are the key challenges that the global Adult Stem Cells market may face in the future?

Which are the leading companies in the global Adult Stem Cells market?

Which are the key trends positively impacting the market growth?

Which are the growth strategies considered by the players to sustain hold in the global Adult Stem Cells market

List of Tables and Figures

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read more here:
Adult Stem Cells Market Demand, Growth Challenges, Industry Analysis And Forecasts To 2026 | Epistem Ltd.,Globalstem,Mesoblast Ltd.,Brainstorm Cell...

ToolGen ties up with 3D bioprinting company to apply induced pluripotent stem cells to gene correction – Aju Business Daily

[Courtesy of ToolGen]

SEOUL --ToolGen, a South Korean developer of genome editing technology, tied up with T&R Biofab, a 3D bioprinting company, to cooperate in applying induced pluripotent stem cells to gene correction. ToolGen has original technology related to third-generation gene scissors to cut out genetic information in cells.

Induced pluripotent stem cells (iPSCs) are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. iPSCs can be derived directly from adult tissues and bypass the need for embryos.

ToolGen signed a memorandum of understanding T&R Biofab, which prints human organs and tissues for clinical transplantation, to develop and utilize cells that combine iPSCs and gene calibration technologies. "Inductive pluripotent stem cells are an ideal platform for developing gene correction therapy because they can be segmented into various cells," said ToolGen co-CEO Kim Young-ho.

ToolGen has partnered with VivaZome Therapeutics, an Australian biotech company, to develop therapies based on exosomes which are recognized for their critical role in cell-to-cell communication and transportation. The market for exosome therapeutics has been growing rapidly, and many life science companies have launched tools and systems to support exosome research.

Read the original here:
ToolGen ties up with 3D bioprinting company to apply induced pluripotent stem cells to gene correction - Aju Business Daily

Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D’OXYVA for Rapid,…

PASADENA, Calif., Feb. 1, 2021 /PRNewswire/ --Circularity Healthcare announced it had successfully executed a contract with the Professional Educational Research Institute (PERI) in 2020 to immediately begin a new clinical trial to study the use of D'OXYVA to help prevent amputations and treat human diabetic foot ulcers at one-tenth the time and cost, and at least five times the efficacy of competing modalities. A widely recognized global clinical research organization (CRO), PERI will specifically study at multiple sites at prestigious U.S. universities the use of D'OXYVA to help address the recent epidemic of DFUs occurring in diabetic patients due to long-term pandemic quarantines and stay-at-home orders. Manufactured by Circularity, D'OXYVA is a painless, noninvasive transdermal delivery system used in minutes to significantly improve blood perfusion, tissue oxygenation, and wound healing even where standard treatments have failed.

"D'OXYVA's pivotal human clinical trial for complete healing of diabetic foot ulcershas been approved by the Western Institutional Review Board (WIRB), the largest in the world, and will include over a dozen high profile research sites at top U.S. universities and clinics," said Senior Sales and Marketing Manager for Circularity, Jennifer Boadilla-Pelaez, RN. "Thousands of competing products in the past nearly twenty-five years have failed in achieving what D'OXYVAhas obtained in terms of regulatory approvals, clinical safety and efficacy in the past seven years. This is truly a game-changing milestone, not just for the company itself, but the entire medical community and the world and a preliminary report with meaningful results is expected within6 months from starting the pivotal trial," said Dr. Charles M. Zelen, PERI's CEO.

DFUs are a major wound complication arising out of diabetes mellitus and occur in 313% of global diabetes patients, affecting millions of people. DFUs are caused by a variety of factors including decreased activity, diminished blood circulation, and people with underlying health conditions like diabetes are at higher risk for complications from COVID-19. Healthcare workers can expect to see far more instances of this persistent problem, especially with quarantine lockdowns, and it represents a significant health and economic risk to both patients and the overall healthcare system. Effective treatments that can reduce DFU recovery time, like D'OXYVA, are absolutely crucial to combatting this newest wound epidemic.

About Circularity Healthcare LLC

Circularity Healthcare is an emerging world leader in proprietary circulatory health and noninvasive delivery technologies, committed to helping improve quality of life by developing, manufacturing, and marketing medical, pharmaceutical, and consumer health products. Circularity specializes in groundbreaking noninvasive technologies for affordable and portable transdermal delivery systems, and is currently pursuing regulatory approval worldwide as a way of treating cardiovascular and microcirculatory blood flow issues, as well as immune and autonomic nervous system disorders. Learn more at: http://www.CircularityHealthcare.com.

About Professional Education and Research Institute, Inc.

PERI was established in 2005 as a premier CRO to manage Phase I - IV clinical trials around the world. PERI conducts clinical trials in both pharmaceutical and orthopedic research and performs specialty research in diabetic wound care, venous leg disease, neuropathy, peripheral vascular disease and gene therapy. One of the most unique advantages of choosing PERI as a partner in clinical trial management is a feature few CRO's can match, which is our contracted sites throughout the United States, including IBC-certified sites. Learn more at: http://www.periedu.com

Media Contact: Jennifer Boadilla-Pelaez 626-240-0956 [emailprotected]

SOURCE Circularity Healthcare LLC

http://www.CircularityHealthcare.com

See original here:
Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D'OXYVA for Rapid,...

Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares

Orphazyme A/SCompany announcement                                                                                       No. 02/2021                                                                                                          Company Registration No. 32266355

Read the original post:
Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Orphazyme A/SCompany announcement                                                                              No. 03/2021                                                                                                  Company Registration No. 32266355

Read the original:
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Revolution Medicines Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock.

Go here to see the original:
Revolution Medicines Announces Proposed Public Offering of Common Stock

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, EyePoint intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering.

Go here to see the original:
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock